Risco cardiovascular em pessoas vivendo com HIV: análise do conceito

Mayara Nascimento de Vasconcelos; George Jó Bezerra Sousa; Sherida Karanini Paz de Oliveira; Rhanna Emanuela Fontenele Lima de Carvalho; Saiwori de Jesus Silva Bezerra dos Anjos; Thereza Maria Magalhães Moreira; Renata Eloah de Lucena Ferretti-Rebustini; Maria Lúcia Duarte Pereira

doi:10.12957/reuerj.2025.86547

Autores/as

Mayara Nascimento de Vasconcelos Universidade Estadual do Ceará https://orcid.org/0000-0002-8731-3215
George Jó Bezerra Sousa Ministério da Saúde https://orcid.org/0000-0003-0291-6613
Sherida Karanini Paz de Oliveira Universidade Estadual do Ceará https://orcid.org/0000-0003-3902-8046
Rhanna Emanuela Fontenele Lima de Carvalho Universidade Estadual do Ceará https://orcid.org/0000-0002-3406-9685
Saiwori de Jesus Silva Bezerra dos Anjos Universidade Estadual do Ceará https://orcid.org/0000-0001-7559-8471
Thereza Maria Magalhães Moreira Universidade Estadual do Ceará https://orcid.org/0000-0003-1424-0649
Renata Eloah de Lucena Ferretti-Rebustini Universidade de São Paulo https://orcid.org/0000-0002-6159-5787
Maria Lúcia Duarte Pereira Universidade Estadual do Ceará https://orcid.org/0000-0002-7685-6169

DOI:

https://doi.org/10.12957/reuerj.2025.86547

Palabras clave:

Enfermería, Enfermedades Cardiovasculares, VIH, Riesgo, Formación de Concepto

Resumen

Objetivo: analizar el concepto de riesgo cardiovascular en personas que viven con VIH. Método: análisis conceptual realizado según las ocho etapas del modelo de Walker y Avant: elección del concepto a analizar, objetivos del análisis conceptual, identificación de posibles usos del concepto, determinación de atributos definitorios, construcción de caso modelo, construcción de caso opuesto, identificación de antecedentes y consecuencias y definición de referencias empíricas. Resultados: el riesgo cardiovascular en personas que viven con VIH puede definirse como una condición multifactorial que se caracteriza por factores de riesgo tradicionales de enfermedades cardiovasculares junto a un estado inflamatorio crónico causado por el VIH, efectos adversos de la terapia antirretroviral y presencia de coinfecciones crónicas. Comprende también identificación de marcadores bioquímicos y cardiovasculares. Conclusión: a partir de los hallazgos, los profesionales y gestores podrán disponer de base científica para planificación en salud, y orientar los pacientes en la adopción de medidas preventivas que forjen hábitos de vida saludables y minimicen eventos cardiovasculares prevalentes en la población con VIH.

Biografía del autor/a

Mayara Nascimento de Vasconcelos, Universidade Estadual do Ceará

Enfermera. Máster en Salud Familiar. Estudiante de Doctorado en Atención Clínica en Enfermería y Salud en la Universidade Estadual do Ceará. Fortaleza, CE, Brasil.

George Jó Bezerra Sousa, Ministério da Saúde

Enfermero. Doctorado en Atención Clínica en Enfermería y Salud. Consultor Técnico del Ministerio de Salud de Brasil, Coordinación General de Vigilancia de la Lepra y Enfermedades en Eliminación. Brasilia, DF, Brasil.

Sherida Karanini Paz de Oliveira, Universidade Estadual do Ceará

Enfermera. Doctorado en Enfermería. Profesora Adjunta del Programa de Postgrado en Atención Clínica en Enfermería y Salud de la Universidade Estadual do Ceará. Fortaleza, CE, Brasil.

Rhanna Emanuela Fontenele Lima de Carvalho, Universidade Estadual do Ceará

Enfermera. Doctorado en Enfermería. Profesora Adjunta del Programa de Postgrado en Atención Clínica en Enfermería y Salud de la Universidade Estadual do Ceará. Fortaleza, CE, Brasil.

Saiwori de Jesus Silva Bezerra dos Anjos, Universidade Estadual do Ceará

Enfermera. Doctorado en Enfermería. Profesora Adjunta del Programa de Postgrado en Atención Clínica en Enfermería y Salud de la Universidade Estadual do Ceará. Fortaleza, CE, Brasil.

Thereza Maria Magalhães Moreira, Universidade Estadual do Ceará

Enfermera. Doctorado en Enfermería. Profesora Adjunta del Programa de Postgrado en Atención Clínica en Enfermería y Salud de la Universidad Estatal de Ceará. Fortaleza, CE, Brasil.

Renata Eloah de Lucena Ferretti-Rebustini, Universidade de São Paulo

Enfermera. Doctorado en Ciencias. Profesora Adjunta II del Departamento de Enfermería Médico-Quirúrgica de la Escuela de Enfermería de la Universidade de São Paulo. São Paulo, SP, Brasil.

Maria Lúcia Duarte Pereira, Universidade Estadual do Ceará

Enfermera. Doctorado en Enfermería. Profesora Adjunta del Programa de Postgrado en Atención Clínica en Enfermería y Salud de la Universidade Estadual do Ceará. Fortaleza, CE, Brasil.

Citas

1. UNAIDS. Joint United Nations Programme on HIV/AIDS. United States of America: UNAIDS; 2020 [cited 2021 Feb 21]. Available from: https://www.unaids.org/en/resources/documents/2020/unaids-data.

2. Ministério da Saúde (Br). Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis (DCCI) Boletim Epidemiológico de HIV e Aids. Brasília: Ministério da Saúde; 2019 [cited 2021 Feb 06]. Available from: http://www.aids.gov.br/pt-br/pub/2019/boletim-epidemiologico-de-hivaids-2019.

3. Ministério da Saúde (Br). Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Boletim Epidemiológico HIV/Aids. Brasília: Ministério da Saúde; 2018 [cited 2021 Feb 06]. Available from: http://www.aids.gov.br/pt-br/pub/2018/boletim-epidemiologico-hivaids-2018.

4. Ministério da Saúde (Br). Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para manejo da infecção pelo HIV em adultos. Brasília: Ministério da Saúde; 2018 [cited 2021 Feb 06]. Available from: http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos.

5. Ministério da Saúde (Br). Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis (DCCI) Relatório de monitoramento clínico do HIV. Brasília: Ministério da Saúde; 2020 [cited 2021 Mar 25]. Available from: http://www.aids.gov.br/pt-br/pub/2020/relatorio-de-monitoramento-clinico-do-hiv-2020.

6. Alonso A, Barnes AE, Guest JL, Shah A, Shao IY, Marconi V. HIV infection and incidence of cardiovascular diseases: an analysis of a large healthcare database. J Am Heart Assoc. 2019 [cited 2022 Mar 25]; 8:e012241. DOI: https://doi.org/10.1161/JAHA.119.012241.

7. Pinto DSM, Silva MJLV. Cardiovascular disease in the setting of human immunodeficiency virus infection. Curr Cardiol Rev. 2018 [cited 2022 Mar 25]; 14:25-41. DOI: https://doi.org/10.2174/1573403X13666171129170046.

8. Bittencourt MS. Estimating Cardiovascular Risk in HIV-Infected Patients. Arq. Bras. Cardiol. 2020 [cited 2022 Mar 25]; 114(1):76-7. DOI: https://doi.org/10.36660/abc.20190747.

9. Erqou S, Lodebo BT, Masri A, Altibi AM, Echouffo-Tcheugui, JB, Dzudie A. Cardiac dysfunction among people living with HIV. JACC Heart Fail. 2019 [cites 2022 Mar 25];7(2):98-108. DOI: https://doi.org/10.1016/j.jchf.2018.10.006.

10. Félix NDC, Cunha BS, Nascimento MNR, Braga DV, Oliveira CJ, Brandão MAG, et al. Analysis of the concept of cardiovascular risk: contributions to nursing practice. Rev Bras Enferm. 2022 [cited 2024 Mar 26];75(4):e20210803. DOI: https://doi.org/10.1590/0034-7167-2021-0803pt.

11. Fernandes MGM, Nóbrega MML, Garcia TR, Macêdo-Costa KNF. Análise conceitual: considerações metodológicas. Rev. bras. enferm. 2011 [cited 2022 Fev 20]; 64(6):1150-6. DOI: https://doi.org/10.1590/S0034-71672011000600024.

12. Walker LO, Avant KC. Strategies for theory construction in nursing. 5th ed. Upper Saddle River: Pearson Prentice Hall; 2011.

13. Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020 [cited 2023 Sep 27]; 18(10):2119–26. DOI: https://doi.org/10.11124/JBIES-20-00167.

14. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018 [cited 2023 Sep 27]; 169(7):467–73. DOI: https://doi.org/10.7326/M18-0850.

15. Silva AG, Paulo RV, Silva-Vergara ML. Aterosclerose carotídea subclínica e DAD Escore Reduzido para Estratificação de Risco Cardiovascular em pacientes HIV positivos. Arq. Bras. Cardiol. 2020 [cited 2022 Mar 25]; 114(1):68-75. Available from: https://abccardiol.org/article/aterosclerose-carotidea-subclinica-e-dad-escore-reduzido-para-estratificacao-de-risco-cardiovascular-em-pacientes-hiv-positivos/.

16. Bazzini D, Pennington LJ, Mejia C. Factores de Riesgo para Enfermedad Cardiovascular en el paciente con Infección por VIH en Guatemala. Rev. med. interna. 2013 [cited 2022 Apr 12]; 17(1):18-23. Avilable from: https://biblioteca.medicina.usac.edu.gt/revistas/revmedi/2013/17/S1/04.

17. Juárez-Ramírez C, Théodore FL, Gómez-Dantés H. Vulnerability and risk: reflections on the COVID-19 pandemic. Rev Esc Enferm USP. 2021 [cited 2024 Mar 26]; 55:e03777. DOI: https://doi.org/10.1590/S1980-220X2020045203777.

18. Antonini M, Melo ES, Costa CRB, Jesus GJ, Gir E, Reis RK. Associação entre hábitos de vida e Risco Cardiovascular em pessoas vivendo com HIV/AIDS. Cogitare Enferm. 2018 [cited 2022 Apr 02]; (23)3:e55217. DOI: https://doi.org/10.5380/ce.v23i3.55217.

19. Manga P, McCutcheon K, Tsabedze K, Vachiat A, Zachariah D. HIV and Nonischemic Heart Disease. J Am Coll Cardiol. 2017 [cited 2022 Apr 02]; 69(1):83-91. DOI: https://doi.org/10.1016/j.jacc.2016.09.977.

20. Haser GC, Sumpio B. Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy. J Vasc Surg 2017 [cited 2022 Apr 02]; 65:849-59. DOI: https://doi.org/10.1016/j.jvs.2016.01.036.

21. Zoest RA, van der Valk M, Wit FW, Vaartjes I, Kooij KW, Hovius JW, Prins M, Reiss P. Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy. Eur J Prev Cardiol. 2017 [cited 2022 Apr 12]; 24(12):1297–307. DOI: http://dx.doi.org/10.1177/2047487317714350.

22. Beltrán SLV, Gualtero SM, Quiroga C, Garzón JR, Mendivelson EL de, Tamara JR, et al. Evaluación y manejo del riesgo cardiovascular en infección por VIH. Consenso de expertos ACIN. Infectio. 2019 [cited 2022 Apr 12]; 23(S1):73-91. DOI: http://dx.doi.org/10.22354/in.v23i1.762.

23. Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, et al. Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. J Am Heart Assoc. 2017 [cited 2022 Apr 12]; 6:e004987. DOI: https://doi.org/10.1161/JAHA.116.004987.

24. Mikuła T, Balsam P, Peller M, Suchacz M, Puchalski B, Kołtowski Ł, et al. The effects of CD4 nadirs on vessel stiffness in HIV patients undergoing antiretroviral therapy. Kardiologia Polska. 2017 [cited 2022 Apr 12]; 75(8):749–57. DOI: http://dx.doi.org/10.5603/KP.a2017.0075.

25. Cahn P, Leite O, Rosales A, Cabello R, Alvarez CA, Seas C, et al. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART. Bras J Infect Dis. 2010 [cited 2022 Apr 12]; 14(2):158-66. DOI: http://dx.doi.org/10.1590/S1413-86702010000200008.

26. Kramer AS, Lazzarotto AR, Sprinz E, Manfroi WC. Alterações Metabólicas, Terapia antirretroviral e doença cardiovascular em idosos portadores de HIV. Arq Bras Cardiol 2009 [cited 2022 Apr 12]; 93(5):561-8. DOI: https://doi.org/10.1590/S0066-782X2009001100019.

27. Policarpo S, Rodrigues T, Moreira AC, Valadas E. Cardiovascular risk in HIV-infected individuals: a comparison of three risk prediction algorithms. Rev Port Cardiol. 2019 [cited 2022 Apr 12]; 38(7):463-70. DOI: http://dx.doi.org/10.1016/j.repc.2019.08.002.

28. Stein JH, Currier JS, Hsue PY. Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us? JACC Cardiovasc Imaging. 2014 [cited 2022 Apr 12]; 7(5):515–25. DOI: http://dx.doi.org/10.1016/j.jcmg.2013.08.019.

29. Eira M, Bensenor IM, Dorea EL, Cunha RS, Mill JG, Lotufo PA. Terapia antirretroviral altamente eficaz para infecção pelo vírus da imunodeficiência humana aumenta a rigidez aórtica. Arq Bras Cardiol. 2012 [cited 2022 Apr 12]; 99(6):1100-7. DOI: http://www.arquivosonline.com.br.

30. Woldu M, Minzi O, Shibeshi W, Shewaamare A, Engidawork E. Predicting the risk of atherosclerotic cardiovascular disease amongadults living with HIV/AIDS in Addis Ababa, Ethiopia: a hospital-based study. PLoSONE 2021 [cited 2022 Apr 25]; 16(11):e0260109. DOI: https://doi.org/10.1371/journal.pone.0260109.

31. Gooden TE, Gardner M, Wang J, Jolly K, Lane DA, Benjamin LA, Mwandumba HC, et al. Incidence of cardiometabolic diseases in people with and without human immunodeficiency virus in the United Kingdom: a population-based matched cohort study. J Infect Dis. 2022 [cited 2022 Apr 25]; 225(8):1348-56. DOI: https://doi.org/10.1093/infdis/jiab420.

32. Neto MG, Zwirtes R, Brites C. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management. Braz J Infect Dis. 2013 [cited 2022 Apr 12]; 17(6):691–700. DOI: http://dx.doi.org/10.1016/j.bjid.2013.05.004.

33. Zanetti HR, Roever L, Gonçalves A, Resende ES. Cardiovascular complications of HIV. Int J Card Sciences. 2018 [cited 2022 Apr 02]; 31(5):538-43. DOI: http://dx.doi.org/10.5935/2359-4802.20180049.

34. Wu PY, Chen MY, Sheng WH, Hsieh SM, Chuang YC, Cheng A, et al. Estimated risk of cardiovascular disease among the HIV-positive patients aged 40 years or older in Taiwan. J Microbiol Immunol Infect. 2019 [cited 2022 Apr 12]; 52(4):549-55. DOI: http://dx.doi.org/10.1016/j.jmii.2019.03.006.

35. Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, et al. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis. 2013 [cited 2022 Apr 12]; 12:50. DOI: http://dx.doi.org/10.1186/1476-511X-12-50.

36. Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep. 2011 [cited 2022 Apr 12]; 13:51–6. DOI: http://dx.doi.org/10.1007/s11883-010-0152-1.

37. Carvalho PVC, Caporali JFM, Vieira ELM, Guimarães NS, Fonseca MO, Tupinambás U. Evaluation of inflammatory biomarkers, carotid intimamedia thickness and cardiovascular risk in HIV-1 treatment-naive patients. Rev Soc Bras Med Trop. 2018 [cited 2022 Apr 12]; 51(3):277-83. DOI: http://dx.doi.org/10.1590/0037-8682-0472-2017.

38. Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency vírus. Vasc Health Risk Manag. 2015 [cited 2022 Apr 02]; 11:35-48. DOI: http://dx.doi.org/10.2147/VHRM.S65885.

39. Kroll AF, Sprinz E, Leal SCL, Labrêa MG, Setúbal S. Prevalence of obesity and cardiovascular risk in patients with HIV/AIDS in Porto Alegre, Brazil. Arq Bras Endocrinol Metab. 2012 [cited 2022 Apr 12]; 56(2):137-41. DOI: http://dx.doi.org/10.1590/S0004-27302012000200007.

40. Bergmann T, Sengupta S, Bhrushundi MP, Kulkarni H, Senguptae PP, Ferguse I. HIV related stigma, perceived social support and risk of premature atherosclerosis in South Asians. I Asians. Indian Heart Journal. 2018 [cited 2022 Apr 12]; 70(5):630–36. DOI: https://doi.org/10.1016/j.ihj.2018.06.018.

41. Agu CE, Uchendu IK, Nsonwu AC, Okwuosa CN, Achukwu PU. Prevalence and associated risk factors of peripheral artery disease in virologically suppressed HIV-infected individuals on antiretroviral therapy in Kwara state, Nigeria: a cross-sectional study. BMC Public Health. 2019 [cited 2022 Apr 12]; 19:1143. DOI: http://dx.doi.org/10.1186/s12889-019-7496-4.

42. Duprez DA, Neuhaus J, Tracy R, Kuller LH, Orkin C, Stoehr A, et al. N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS. 2011 [cited 2022 Apr 25]; 25(5):651–7. DOI: http://dx.doi.org/10.1097/QAD.0b013e32834404a1.

43. Vilela FD, Rocha AL, Rangel BT, Ianini GF, Hadlich M, Barros MV L, et al. Risk of coronary artery disease in individuals infected with human immunodeficiency virus. Braz J Infect Dis. 2011 [cited 2022 Apr 25]; 15(6):521-7. DOI: http://dx.doi.org/10.1590/S1413-86702011000600004.

44. Del Pino PL, León-Amenero G, Leiva-Montejo A, Segura ER. Concordancia entre las escalas de riesgo cardiovascular Procam y Framingham en varones que reciben tratamiento antirretroviral en un Hospital Nacional de Lima, Perú 2013. Rev. perú. med. exp. salud publica. 2015 [cited 2022 Apr 25]; 32(4):731-8. Available from: http://www.scielo.org.pe/scielo.php?pid=S1726-46342015000400015&script=sci_abstract.

45. Muller EV, Gimeno SGA. Risk factors for cardiovascular disease in HIV/AIDS patients treated with highly active antiretroviral therapy (HAART) in the central-southern region of the state of Paraná – Brazil. Ciênc. saúde coletiva. 2019 [cited 2022 Apr 12]; 24(5):1903-14. DOI: https://doi.org/10.1590/1413-81232018245.16682017.

46. Echeverría P, Domingo P, Llibre JM, Gutierrez M, Mateo G, Puig J, et al. Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients. BioMed Research International. 2014 [cited 2022 Apr 12]; 2014:823058. DOI: https://doi.org/10.1155/2014/823058.

47. So-Armah K, Freiberg MS. HIV and cardiovascular disease: update on clinical events, special populations, and novel biomarkers. Curr HIV/AIDS Rep. 2018 [cited 2022 Apr 12]; 15(3):233–44. DOI: http://dx.doi.org/10.1007/s11904-018-0400-5.

48. Polanka BM, Gupta SK, So-Armah KA, Freiberg MS, Zapolski TCB, Hirsh AT, et al. Examining depression as a risk factor for cardiovascular disease in people with HIV: a systematic review. Ann Behav Med. 2023 [cited 2022 Apr 12]; 57(1):1-25. DOI: http://dx.doi.org/10.1093/abm/kaab119.

49. Diaz CM, Segura ER, Luz PM, Clark JL, Ribeiro SR, Boni RD, et al. Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study. BMC Infecti Dis.2016 [cited 2022 Apr 25]; 16:376. DOI: http://dx.doi.org/10.1186/s12879-016-1735-4.

50. Melo ES, Antonini M, Costa CRB, Pontes PS, Gir E, Reis RK. Validation of an interactive electronic book for cardiovascular risk reduction in people living with HIV. Rev. Latino-Am. Enfermagem. 2022 [cited 2022 Apr 25]; 30:e3512. DOI: http://dx.doi.org/10.1590/1518-8345.5568.3512.

51. Leite LHM, Sampaio ABMM. Risco cardiovascular: marcadores antropométricos, clínicos e dietéticos em indivíduos infectados pelo vírus HIV. Rev Nutr. 2011 [cited 2022 Apr 25]; 24(1):79-88. DOI: http://dx.doi.org/10.1590/S1415-52732011000100008.

52. Muniz CG, Brito C. O que representa o diagnóstico de HIV/Aids após quatro décadas de epidemia? Saúde debate. 2022Oct [cited 2024 Mar 26]; 46(135):1093–106. DOI: https://doi.org/10.1590/0103-1104202213510.

53. Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010 [cited 2022 Apr 25]; 17(5):491-501. DOI: http://dx.doi.org/10.1097/HJR.0b013e328336a150.

54. Friis-Moller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons; the Data-collection on Adverse Effects of Anti-HIV Drugs (DAD) Study. Eur J Prev Cardiol. 2016 [cited 2022 Apr 25]; 23(2):214-23. DOI: http://dx.doi.org/10.1177/2047487315579291.